Rhythm Pharmaceuticals, based in Boston, develops therapeutics for rare diseases, focusing on melanocortin-4 receptor agonists like IMCIVREE, approved for chronic weight management in specific obesity cases. The company employs 226 people and went public in October 2017.
David P Meeker sold 43,620 shares of RYTM on 3 June at $65.60 per share, worth a total of $2.9M. They now own 202,099 RYTM shares, or a 18% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
